Enobosarm in AR-positive, ER-positive, and HER2-Negative Advanced Breast Cancer | 2 Minute Medicine
2 Minute Medicine ,
1. The clinical benefit rate was 32% in the 9 mg group and 29% in the 18 mg group.
1. The clinical benefit rate was 32% in the 9 mg group and 29% in the 18 mg group.
An international group of researchers have conducted a clinical trial of a new breast cancer drug with fewer side effects…
For years, breast cancer treatment has focused on blocking estrogen, but a new global study has found a less toxic way to…
For decades, hormonal treatment of breast cancer has been going in one direction blocking oestrogen.